# GANX catalysts: Gain Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ganx/catalysts

> Gain Therapeutics, Inc. (GANX) has 3 upcoming catalysts. The next is the rexaceract trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for GANX?

Gain Therapeutics, Inc. (GANX) has 3 upcoming catalysts. The next is the rexaceract trial start, Q1 2027. Press release filed with the SEC (EX-99): "Initiation of rexaceract Phase 2 clinical trial expected during Q1 2027 following a comprehensive redesign and submission of new Phase 2 protocol." [Calendar and source filings](https://sec-api.dev/companies/ganx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-125159, https://www.sec.gov/Archives/edgar/data/1819411/000110465926125159/ganx-ex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/ganx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Gain Therapeutics, Inc. |
| Ticker | GANX (Nasdaq) |
| SEC CIK | 1819411 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ganx |

## Cash runway

Cash $11.7M as of 2026-09-30; quarterly burn $3.0M; about 11.5 months of runway at that rate (XBRL company facts, accession 0001104659-26-125167).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 14, 2024 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/ganx-20241114xex99d1.htm)) |
| March 27, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/ganx-20250327xex99d1.htm)) |
| Q2 2025 | [Glucocerebrosidase interim data readout](https://sec-api.dev/pdufa/glucocerebrosidase) | GANX |  | scheduled | "We expect to provide an enrollment update by the end of 1Q 2025 and guidance in 2Q 2025 when we expect to be in position to discuss interim analysis of the Phase 1b clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/tm255679d1_ex99-1.htm)) |
| May 14, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/ganx-20250514xex99d1.htm)) |
| 2H 2025 | [Glucocerebrosidase trial start](https://sec-api.dev/pdufa/glucocerebrosidase) | GANX |  | scheduled | "We do not expect our capital requirements to change significantly until we commence planning for our Phase 2 studies, anticipated in 2H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/tm255679d1_ex99-1.htm)) |
| August 12, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/ganx-20250812xex99d1.htm)) |
| November 12, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/ganx-20251112xex99d1.htm)) |
| March 26, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926035174/ganx-20260326xex99d1.htm)) |
| May 11, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/ganx-20260511xex99d1.htm)) |
| Q3 2026 | [Rexaceract trial start](https://sec-api.dev/pdufa/rexaceract) | GANX | Parkinson's disease | scheduled | "In June 2026, The Company has received Investigational New Drug (IND) authorization from the FDA to commence a Phase 2 study of rexaceract in people with Parkinson's disease, anticipated to begin in the third quarter of 2026 across sites in the United States, Australia, and Europe." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819411/000110465926094048/ganx-20260630x10q.htm)) |
| August 11, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/ganx-20260811xex99d1.htm)) |
| November 10, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926125159/ganx-ex99d1.htm)) |
| Q1 2027 | [Rexaceract trial start](https://sec-api.dev/pdufa/rexaceract) | GANX | Parkinson's disease | scheduled | "Initiation of rexaceract Phase 2 clinical trial expected during Q1 2027 following a comprehensive redesign and submission of new Phase 2 protocol." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926125159/ganx-ex99d1.htm)) |
| Jun to Sep 2028 | [Low dose gt-02287 topline data readout](https://sec-api.dev/pdufa/low-dose-gt-02287) | GANX | Parkinson Disease | scheduled | "NCT07280299 (Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Gain Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07280299)) |
| June 2028 | [Low dose gt-02287 primary completion](https://sec-api.dev/pdufa/low-dose-gt-02287) | GANX | Parkinson Disease | scheduled | "NCT07280299 (Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Gain Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07280299)) |

## Drugs

- [Glucocerebrosidase](https://sec-api.dev/pdufa/glucocerebrosidase): 
- [Low dose gt-02287](https://sec-api.dev/pdufa/low-dose-gt-02287): Parkinson Disease
- [Rexaceract](https://sec-api.dev/pdufa/rexaceract): parkinson's disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ganx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GANX catalysts: Gain Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ganx/catalysts

```bibtex
@misc{secapidev_companies_ganx_catalysts_20261116,
  title        = {GANX catalysts: Gain Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ganx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ganx_catalysts_20261116","title":"GANX catalysts: Gain Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ganx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
